Assessing Nektar Therapeutics (NASDAQ:NKTR) Stock & NKTR-181 Commercial Outlook After 42% Move

Is NKTR stock still a good buy after its 40% move higher, after Nektar Therapeutics (NASDAQ:NKTR) strong NKTR-181 data?

Posted in Biotech Hunter, Healthcare & Biotech, Members, Request Coverage | Tagged , , , | Leave a comment

What Pfizer Inc (NYSE:PFE), Intel Corporation (NASDAQ:INTC), & Gilead Sciences (NASDAQ:GILD) Have In Common

Pfizer (NYSE:PFE) & Intel Corporation (NASDAQ:INTC) paid big bucks for growth, but Mobileye NV (NYSE:MBLY) is a bet on innovation.

Posted in Hot Stocks, Mergers & Acquisitions | Tagged , , , , , , , | Leave a comment

ACADIA Pharmaceuticals (ACAD) Buyout: Why The AstraZeneca (AZN) Rumor Matters

A bidding war for Acadia Pharmaceuticals and Nuplazid is likely to ensue after buyout rumors last Friday. Great news for ACAD stock owners.

Posted in Editor's Pick, Healthcare & Biotech, Members, Mergers & Acquisitions | Tagged , , , , , | Leave a comment

Why Acadia Pharmaceuticals (ACAD) Will Get More Than $44 From Pfizer (PFE)

Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma

Posted in Healthcare & Biotech, Members, Mergers & Acquisitions | Tagged , , , , , , , , | 1 Comment

10 Acquisition Predictions For 2017: VRX, GILD, AmEx, SPLK, WFM

Acquisition predictions for 2017 that include VRX, GILD, AmEx, SPLK, & WFM being bought, and Takeda, Pfizer, Apple, IBM, and Kroger spending big.

Posted in Members, Mergers & Acquisitions | Tagged , , , , , , , , , , , , , , , , | Leave a comment

10 Dividend Stocks You Must Own In 2017: GILD, AT&T, SBGL, PFE, BP

In part 1 of a 2-part series David examines his top dividend stocks for 2017, which include GILD, AT&T, SBGL, PFE, and BP.

Posted in David's Dividends, Members, Portfolio Strategy | Tagged , , , , , , , , | Leave a comment

What Dividend Stocks & Growth Stocks To Buy For $30,000 Profits Each Year

Four dividend stocks and two growth stocks to buy that will yield a $30,000 annual return or more on $250,000 over the next decade.

Posted in Build My Portfolio, Members | Tagged , , , , , , , | Leave a comment